Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus concurrent chemoradiotherapy in locally advanced cervical cancer
ChiCTR2400086780Phase 2Not yet recruiting
- Sponsor
- Meishan Municipal People's Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Meishan Municipal People's Hospital. Primary endpoints: objective response rate and safety. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400086780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086780.